"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super Bowl ad, leveling the accusation against brand-name weight loss drugs. Set to the tune of Childish Gambino’s “This Is America,

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.

The sum for semaglutide has been clocked up in just over a year, it has emerged – but the Ministry of Defence claims obesity levels in the Armed Forces are 'extremely low'

A Super Bowl ad touting Hims & Hers Health Inc.’s copycat weight-loss drugs is getting pushback from the branded drugmakers’ lobbying group, which says it’s “misleading” and potentially violates marketing rules.

Hims & Hers Health is set to have a commercial air during Super Bowl LIX. It’s already courting controversy, with calls to bar the game’s host, Fox, from broadcasting it. Why? Experts, advocates and politicians are saying that the 60-second spot — which deems obesity “America’s deadliest epidemic,

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to a new study.